Fecal microbiota transplantation as a new way for OVA-induced atopic dermatitis of juvenile mice.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 100965259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-1705 (Electronic) Linking ISSN: 15675769 NLM ISO Abbreviation: Int Immunopharmacol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Amsterdam ; New York : Elsevier Science, c2001-
    • Subject Terms:
      Dermatitis, Atopic*/therapy ; Dermatitis, Atopic*/immunology ; Dermatitis, Atopic*/microbiology ; Fecal Microbiota Transplantation* ; Ovalbumin*/immunology ; Gastrointestinal Microbiome*/immunology ; Disease Models, Animal*; Animals ; Mice ; Mice, Inbred BALB C ; Immunoglobulin E/blood ; Immunoglobulin E/immunology ; T-Lymphocytes, Regulatory/immunology ; Female ; Skin/pathology ; Skin/immunology ; Skin/microbiology ; Programmed Cell Death 1 Receptor/metabolism ; B7-H1 Antigen/metabolism ; B7-H1 Antigen/genetics ; Humans ; Allergens/immunology ; Immune Tolerance ; Cytokines/metabolism
    • Abstract:
      Children all over the world suffer from atopic dermatitis (AD), a prevalent condition that impairs their health. Corticosteroids, which have long-term negative effects, are frequently used to treat AD. There has been a growing body of research on the gut microbiota's function in AD. Nevertheless, the function and underlying mechanisms of fecal microbiota transplantation (FMT) in AD children remain to be established. Therefore, in order to assess the preventive effects of FMT treatment on AD and investigate the mechanisms, we constructed an ovalbumin (OVA)-induced juvenile mouse AD model in this investigation. This study explored the role and mechanism of FMT treatment in AD through 16S RNA sequencing, pathological histological staining, molecular biology, and Flow cytometry. Results demonstrated that the FMT treatment improved the gut microbiota's diversity and composition, bringing it back to a level similar to that of a close donor. Following FMT treatment, OVA-specific antibodies were inhibited, immunoglobulin (Ig) E production was decreased, the quantity of mast cells and eosinophils was decreased, and specific inflammatory markers in the skin and serum were decreased. Further mechanistic studies revealed that FMT treatment induced CD103 + DCs and programmed cell death ligand 1 (PD-L1)/programmed cell death 1 (PD-1) expression in skin-draining lymph nodes and promoted Treg production to induce immune tolerance and suppress skin inflammation. Meanwhile, changes in the gut microbiota were substantially correlated with Th2 cytokines, OVA-specific antibodies, and PD-L1/PD-1. In conclusion, FMT regulates the Th1/Th2 immunological balance and the gut microbiota. It may also inhibit AD-induced allergy responses through the PD-L1/PD-1 pathway, and providing a unique idea and possibly a fresh approach to the treatment of AD.
      Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
      (Copyright © 2024. Published by Elsevier B.V.)
    • Contributed Indexing:
      Keywords: Allergic diseases; Atopic dermatitis; Fecal microbiota transplantation (FMT); Gut microbiota; PD-L1/PD-1 pathway
    • Accession Number:
      9006-59-1 (Ovalbumin)
      37341-29-0 (Immunoglobulin E)
      0 (Programmed Cell Death 1 Receptor)
      0 (B7-H1 Antigen)
      0 (Allergens)
      0 (Cytokines)
      0 (Pdcd1 protein, mouse)
    • Publication Date:
      Date Created: 20240919 Date Completed: 20241011 Latest Revision: 20241011
    • Publication Date:
      20241011
    • Accession Number:
      10.1016/j.intimp.2024.113183
    • Accession Number:
      39298815